CompletedPhase 1

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess Pharmacokinetic and Pharmacodynamic Effects of CT-868 on the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM

Lead sponsor

Carmot Therapeutics, Inc.

Asset

CT-868

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 30-35•Healthy volunteers

Primary endpoint

•Insulin secretion rate and ambient glucose levels

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04973111

Org study IDCT-868-003

Timeline

Milestones

Study start2021-07-16actual

Study first posted2021-07-22actual

Primary completion2022-04-22actual

Study completion2022-04-22actual

Last update posted2025-03-28actual

Assets

Investigational agents

CT-868

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Part 1: Obese Otherwise Healthy Males

•Part 2: Males or Females with T2D

•Part 1: BMI 30.0-35.0, inclusive

•Part 2: BMI 27.0-45.0, inclusive

•18-65 years old, inclusive

•Stable body weight for 2 months

Exclusion criteria

•Significant medical history

•Uncontrolled hypertension

•History of malignancy

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint/low confidence

Change in insulin secretion rate and ambient glucose levels

Time frame:Baseline up to 4 days

change from baseline, improvement

Secondary/protocol endpoint

Change in blood insulin levels at each level of glucose infusion

Time frame:Baseline up to 4 days

change from baseline, improvement

Secondary/protocol endpoint

Change in blood glucose levels at each level of glucose infusion

Time frame:Baseline up to 4 days

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.